Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP).

Full DD Report for TNXP

You must become a subscriber to view this report.


Recent News from (NASDAQ: TNXP)

Tonix Pharmaceuticals Announces New Board Member, Oye Olukotun, M.D.
NEW YORK, Sept. 07, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) today announced the appointment of Adeoye “Oye” Olukotun, M.D. to its Board of Directors, effective immediately.  Dr. Olukotun assumes the seat held by Dr. Ernest Mario...
Source: GlobeNewswire
Date: September, 07 2018 07:00
Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences
NEW YORK, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present a company overview at two investor conferences in September. Details of the presen...
Source: GlobeNewswire
Date: August, 30 2018 07:00
Biotech Analysis Central Pharma News: Allergan's CRL, Tonix Pharmaceutical's Potential Reversal, AstraZeneca's Tagrisso Win
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Allergan Receives Complete Response Letter For Uterine Fibroid Drug News: Recently, Allergan ( AGN ) announced that it had received a complete resp...
Source: SeekingAlpha
Date: August, 24 2018 09:12
Tonix Pharmaceuticals Could Fall Hard Ahead
Tonix Pharmaceuticals ( TNXP ) saw a steady rise in value on Tuesday, August 22, 2018, after reporting that a subset of data from a failed Phase 3 clinical trial showed promise. There is little chance that this announcement will lead to anything of real value in the future. It's also worth tak...
Source: SeekingAlpha
Date: August, 24 2018 09:12
Tonix Pharmaceuticals Announces Director Stepping Down
NEW YORK, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Samuel Saks, M.D. has stepped down from the Company’s board of directors, effective August 21, 2018. Dr. Saks has served on the Board of Directors of Tonix sinc...
Source: GlobeNewswire
Date: August, 22 2018 16:01
Aptinyx presents preclinical data on PTSD candidate NYX-783; shares up 1%
Aptinyx ( APTX +0.7% ) announces a poster presentation at the Military Health System Research Symposium related to preclinical data on posttraumatic stress disorder (PTSD) candidate NYX-783, an NMDA receptor modulator that it says represents a paradigm shift for treating the condition. ...
Source: SeekingAlpha
Date: August, 21 2018 10:12
Premarket Gainers as of 9:05 am (08/21/2018)
TNXP +15%  on potential subgroup of PTSD sufferers who may benefit from Tonmya. More news on: Tonix Pharmaceuticals Holding Corp., Cronos Group, Inc., Toll Brothers Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 21 2018 09:15
Tonix Pharma up 25% premarket on potential subgroup of PTSD sufferers who may benefit from Tonmya
Nano cap Tonix Pharmaceuticals (NASDAQ: TNXP ) is up  25%  premarket on light volume on the heels of its announcement of a ray of hope for Tonyma (cyclobenzaprine HCl sublingual tablets) for the treatment of posttraumatic stress disorder (PTSD). More news on: Tonix Pharmaceutic...
Source: SeekingAlpha
Date: August, 21 2018 07:46
Tonix Pharmaceuticals Presents Results and Retrospective Analyses of Two Double-Blind, Randomized Placebo-Controlled 12-Week Studies of Tonmya® in Military-Related PTSD at the 2018 Military Health System Research Symposium
Retrospective Analysis of the Discontinued Phase 3 P301 “HONOR” Study Revealed Clinically Meaningful Response to Tonmya in PTSD Participants with Trauma Experienced Within Nine Years Prior to Screening but Not in Participants with Trauma Experienced More Than Nine Years Prior...
Source: GlobeNewswire
Date: August, 21 2018 07:00
Tonix Pharma still clawing back, up 8%
Nano cap Tonix Pharmaceutical Holding ( TNXP +7.9% ) jumps on more than triple normal volume. Shares have regained almost  50%  since touching $0.89 on July 27 after announcing the Tonmya flop in PTSD. More news on: Tonix Pharmaceuticals Holding Corp., Healthcare stocks news, S...
Source: SeekingAlpha
Date: August, 20 2018 11:36

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-122.772.87992.912.73470,575
2018-12-112.902.76572.902.75338,710
2018-12-102.902.72932.932.64420,970
2018-12-076.252.96047.24062.845,567,556
2018-12-063.943.14093.943.03683,489

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1283,440141,39859.0107Short
2018-12-1133,14472,83645.5050Short
2018-12-1069,091122,80056.2630Short
2018-12-07653,0021,171,13255.7582Short
2018-12-0695,579166,37657.4476Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on TNXP.


About Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP)

Logo for Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP)

Not available

 

Contact Information

 

 

Current Management

  • Seth Lederman / CEO, President
  • Leland Gershell / CFO
  • Seth Lederman / Chairman
  • Stuart Davidson /
  • Patrick Grace /
  • Donald Landry /
  • Ernest Mario /
  • Charles Mather /
  • John Rhodes /
  • Samuel Saks /

Current Share Structure

  • Market Cap: $23,020,580 - 05/11/2018
  • Authorized: 150,000,000 - 05/01/2018
  • Issue and Outstanding: 8,340,790 - 05/01/2018

 


Recent Filings from (NASDAQ: TNXP)

Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: May, 17 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: May, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Simplified registration form
Filing Type: S-3Filing Source: edgar
Filing Date: May, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 01 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018

 

 


Daily Technical Chart for (NASDAQ: TNXP)

Daily Technical Chart for (NASDAQ: TNXP)


Stay tuned for daily updates and more on (NASDAQ: TNXP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: TNXP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in TNXP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of TNXP and does not buy, sell, or trade any shares of TNXP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/